GlassScriptPhysician profile
Kurt Thomas Jackson
NPI 1619161858
$10,643.28
in general payments reported to CMS, 2019-2025
27 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 83% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,011 · 2020: $2,386 · 2021: $690 · 2022: $780 · 2023: $1,371 · 2024: $1,346 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,364 · Travel and Lodging: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,364.32 |
| Travel and Lodging | $411.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Tcrc, INC. | $2,357.75 | 2020 | |
| Genentech, INC. | $1,853.24 | 2019-2023 | Vabysmo |
| Abbvie INC. | $1,338.57 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $796.42 | 2022-2025 | Stellaris, Envista Mx60 Iol, Stellaris Elite |
| Apellis Pharmaceuticals, INC. | $625.70 | 2023-2025 | Syfovre |
| Allergan, INC. | $592.96 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $552.32 | 2022-2025 | Eylea Hd, Eylea |
| Dompe US, INC. | $492.01 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $347.16 | 2023-2025 | |
| Astellas Pharma US INC | $263.99 | 2023-2025 | Izervay |
| Oyster Point Pharma, INC. | $202.55 | 2023-2025 | Tyrvaya |
| Sight Sciences, INC. | $181.92 | 2021-2024 | Omni Surgical System |
| Genentech USA, INC. | $174.55 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $163.84 | 2024-2025 | Xdemvy |
| Alimera Sciences, INC. | $131.22 | 2019-2023 | Iluvien |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $115.06 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $85.31 | 2023-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Sun Pharmaceutical Industries INC. | $83.34 | 2023-2025 | Cequa |
| Alcon Vision LLC | $81.99 | 2022-2025 | Eysuvis, Rocklatan |
| Mallinckrodt Hospital Products INC. | $70.66 | 2024-2025 | Acthar |
| Thea Pharma INC. | $38.60 | 2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $26.03 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.84 | 2021 | |
| Novo Nordisk INC | $14.98 | 2025 | Wegovy |
| Harrow Eye, LLC | $14.82 | 2023 | Iheezo |
| Tearlab Corp | $14.45 | 2023 | Tearlab Osmolarity System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.